indolin-6-ylmethanol | 1314908-30-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: indolin-6-ylmethanol
• 英文别名: 2,3-dihydro-1H-indol-6-ylmethanol
• CAS: 1314908-30-9
• 化学式: C₉H₁₁NO
• mdl: MFCD03095264
• 分子量: 149.192
• InChiKey: ASGMIPKABNEUSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  indolin-6-ylmethanol 在 四溴化碳 、 三苯基膦 作用下， 以 氯仿 、 乙腈 为溶剂， 反应 12.17h， 生成 1-Boc-6-(imidazol-1-yl)methylindoline
  参考文献：
  名称：

  一系列具有自由基清除和抗过氧化活性的血栓烷A2合成酶抑制剂。

  摘要：

  合成了一系列具有咪唑和羧基部分的吲哚啉衍生物，并评估了它们对血栓烷A2（TXA2）合成酶的抑制，自由基清除和抗过氧化活性。在合成的化合物中，3- [5-取代的-3- [2-（咪唑-1-基）乙基]吲哚-1-基]丙酸显示出自由基清除活性，并且对大鼠脑匀浆脂质过氧化具有抑制作用以及花生四烯酸酯诱导的兔血小板依赖TXA2的聚集。抗血小板和抗过氧化活性与5-取代基的亲脂性有关。5-己氧基衍生物（13）对TXA2合成的抑制活性比奥扎格雷高约35倍，对脂质过氧化的活性比α-生育酚高约100倍。

  DOI：

  10.1248/cpb.49.563
• 作为产物：
  描述：

  吲哚-6-甲醇 在 sodium cyanoborohydride 、 溶剂黄146 作用下， 生成 indolin-6-ylmethanol
  参考文献：
  名称：

  A Divergent SAR Study Allows Optimization of a Potent 5-HT_2c Inhibitor to a Promising Antimalarial Scaffold

  摘要：

  From the 13 533 chemical structures published by GlaxoSmithKline in 2010, we identified 47 quality starting points for lead optimization. One of the most promising hits was the TCMDC-139046, a molecule presenting an indoline core, which is well-known for its anxiolytic properties by interacting with serotonin antagonist receptors 5-HT2. The inhibition of this target will complicate the clinical development of these compounds as antimalarials. Herein, we present the antimalarial profile of this series and our efforts to avoid interaction with this receptor, while maintaining a good antiparasitic potency. By using a double-divergent structure-activity relationship analysis, we have obtained a novel lead compound harboring an indoline core.

  DOI：

  10.1021/ml300008j

文献信息

• Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof
  申请人：Tsou Hwei-Ru

  公开号：US20080085890A1

  公开（公告）日：2008-04-10

  This invention provides compounds of Formula (I), having the structure where G 1 , G 2 , G 3 , G 4 , A 1 , A 2 , Y 1 , Y 2 , L 1 , Z, e and f are defined herein, or a pharmaceutically acceptable salt thereof, which are useful for treating or preventing cancer.

  这项发明提供了具有结构的化合物（I），其中G1、G2、G3、G4、A1、A2、Y1、Y2、L1、Z、e和f在此处定义，或其药用可接受盐，用于治疗或预防癌症。
• [EN] IMIDAZOPYRIDAZINE AND IMIDAZOTHIADIAZOLE COMPOUNDS<br/>[FR] COMPOSÉS IMIDAZOPYRIDAZINE ET IMIDAZOTHIADIAZOLE
  申请人：UNIV MONTREAL

  公开号：WO2016134450A1

  公开（公告）日：2016-09-01

  The present invention provides imidazopyridazine compounds or imidazothiadiazole compounds of Formula I having the structure: (I) wherein X1, X2, X3, X4, X5, Y, W, R1, R2, R3, R4, R5 and (II) are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

  本发明提供了具有以下结构的咪唑吡啶嗪化合物或咪唑硫代噻唑化合物的公式I：（I）其中X1、X2、X3、X4、X5、Y、W、R1、R2、R3、R4、R5和（II）如本文所定义，或其立体异构体、互变异构体、药用可接受盐、前药酯或溶剂化合物形式。这些化合物是血小板聚集抑制剂，因此可以用作治疗或预防血栓栓塞性疾病的药物。
• PPAR active compounds
  申请人：Arnold James

  公开号：US20080096913A1

  公开（公告）日：2008-04-24

  Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.

  描述了对PPARs活性的化合物，包括全谱活性化合物。还描述了开发或鉴定具有所需选择性配置文件的化合物的方法。
• PPAR ACTIVE COMPOUNDS
  申请人：Arnold James

  公开号：US20100210036A1

  公开（公告）日：2010-08-19

  Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.

  描述了对PPARs有活性的化合物，包括全能化合物。还描述了开发或识别具有所需选择性配置文件的化合物的方法。
• HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS
  申请人：Zhu Zhaoning

  公开号：US20100292203A1

  公开（公告）日：2010-11-18

  Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(═S)—, —S(O)—, —S(O) 2 —, —C(═O)—, —O—, —C(R 6 )(R 7 )—, —N(R 5 )— or —C(═N(R 5 ))—; X is —O—, —N(R 5 )— or —C(R 6 )(R 7 )—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O) 2 —, —C(═O)— or —C(═NR 5 )—; U is a bond, —S(O)—, —S(O) 2 —, —C(O)—, —O—, —P(O)(OR 15 )—, —C(═NR 5 )—, —(C(R 6 )(R 7 )) b — or —N(R 5 )—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O) 2 —, —O—, or —N(R 5 )—, U is not —S(O)—, —S(O) 2 —, —O—, or —N(R 5 )—; provided that when X is —N(R 5 )— and W is —S(O)—, —S(O) 2 —, —O—, or —N(R 5 )—, then U is not a bond; and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m 1 agonist or m 2 antagonist.

  本发明公开了式I的化合物或其立体异构体、互变异构体、药学上可接受的盐或溶剂，其中W是键，—C(═S)—、—S(O)—、—S(O)2—、—C(═O)—、—O—、—C(R6)(R7)—、—N(R5)—或—C(═N(R5))—；X是—O—、—N(R5)—或—C(R6)(R7)—；但当X为—O—时，U不是—O—、—S(O)—、—S(O)2—、—C(═O)—或—C(═NR5)—；U是键，—S(O)—、—S(O)2—、—C(O)—、—O—、—P(O)(OR15)—、—C(═NR5)—、—(C(R6)(R7))b—或—N(R5)—；其中b为1或2；但当W为—S(O)—、—S(O)2—、—O—或—N(R5)—时，U不是—S(O)—、—S(O)2—、—O—或—N(R5)—；但当X为—N(R5)—且W为—S(O)—、—S(O)2—、—O—或—N(R5)—时，U则不是键；R1、R2、R3、R4、R5、R6和R7如说明书所定义；以及包含式I化合物的药物组合物。本发明还公开了抑制天冬氨酸蛋白酶的方法，特别是治疗心血管疾病、认知和神经退行性疾病的方法，以及抑制人类免疫缺陷病毒、质膜蛋白酶、组织蛋白酶D和原虫酶的方法。本发明还公开了使用式I化合物与胆碱酯酶抑制剂或肌动蛋白M1激动剂或M2拮抗剂相结合治疗认知或神经退行性疾病的方法。